• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Network Meta-Analysis Comparing Apixaban Versus Rivaroxaban in Morbidly Obese Patients With Atrial Fibrillation.

作者信息

Kido Kazuhiko, Shimizu Mikiko, Shiga Tsuyoshi, Hashiguchi Masayuki

机构信息

Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, West Virginia.

Department of Pharmaceutics and Pharmacometrics, School of Pharmacy, Shujitsu University, Okayama, Japan.

出版信息

Am J Cardiol. 2020 Nov 1;134:160-161. doi: 10.1016/j.amjcard.2020.09.003. Epub 2020 Sep 9.

DOI:10.1016/j.amjcard.2020.09.003
PMID:32916147
Abstract
摘要

相似文献

1
Network Meta-Analysis Comparing Apixaban Versus Rivaroxaban in Morbidly Obese Patients With Atrial Fibrillation.比较阿哌沙班与利伐沙班在病态肥胖房颤患者中的网状Meta分析
Am J Cardiol. 2020 Nov 1;134:160-161. doi: 10.1016/j.amjcard.2020.09.003. Epub 2020 Sep 9.
2
Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.阿哌沙班与利伐沙班治疗心房颤动患者的有效性和安全性
Ann Intern Med. 2020 Apr 7;172(7). doi: 10.7326/P20-0003. Epub 2020 Mar 10.
3
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.利伐沙班与阿哌沙班治疗房颤患者的主要缺血或出血事件的相关性。
JAMA. 2021 Dec 21;326(23):2395-2404. doi: 10.1001/jama.2021.21222.
4
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.非维生素 K 拮抗剂口服抗凝剂在非瓣膜性心房颤动中预防卒中的直接比较有效性和安全性：观察性研究的系统评价和荟萃分析。
Eur J Epidemiol. 2019 Feb;34(2):173-190. doi: 10.1007/s10654-018-0415-7. Epub 2018 Jun 8.
5
Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.不同口服抗凝剂在伴有严重慢性肾脏病的心房颤动患者中的大出血、卒中和全身性栓塞及死亡风险。
J Am Heart Assoc. 2024 Aug 20;13(16):e034641. doi: 10.1161/JAHA.123.034641. Epub 2024 Aug 9.
6
Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study.阿哌沙班与利伐沙班用于常规治疗的房颤患者的有效性和安全性：一项队列研究。
Ann Intern Med. 2020 Apr 7;172(7):463-473. doi: 10.7326/M19-2522. Epub 2020 Mar 10.
7
Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation.Xa 因子抑制剂与华法林在病态肥胖合并心房颤动患者中的比较。
Eur J Clin Pharmacol. 2024 Jul;80(7):1039-1050. doi: 10.1007/s00228-024-03672-y. Epub 2024 Mar 20.
8
Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population.医疗保险人群中从华法林转换为直接口服抗凝剂的非瓣膜性心房颤动患者的有效性和安全性
Adv Ther. 2025 Mar;42(3):1462-1483. doi: 10.1007/s12325-024-03099-y. Epub 2025 Jan 30.
9
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
10
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.阿哌沙班与华法林相比在心房颤动合并外周动脉疾病患者中的疗效和安全性：来自ARISTOTLE试验的见解
J Am Heart Assoc. 2017 Jan 17;6(1):e004699. doi: 10.1161/JAHA.116.004699.

引用本文的文献

1
Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO).肥胖与心房颤动患者的直接口服抗凝剂：意大利国家医院心脏病专家协会（ANMCO）立场文件
J Clin Med. 2021 Sep 16;10(18):4185. doi: 10.3390/jcm10184185.